pAlb-hLPA-Tg(V2)

Nomenclature

C57BL/6JSmo-Tgtn(pAlb-hLPA-3’UTR-pA)1Smoc

Cat. NO.

NM-TG-231782

Strain State

Repository Live

Export PDF

Model Description

These transgenic strains harbor pAlb-hLPA-3’UTR-pA expression cassettes.

Validation Data

image.png

Fig.1 Detection of hLPA expression in serum by ELISA. 

Abbr. WT, wild type.

image.png

Fig.2 Detection of serum hLPA protein level (A) and inhibiton ratio (B) after single dose of test compound (male, n=5/group). (Data from a collaborator)

 image.png

Fig.3 Detection of human LPA inhibition by Lepodisiran. Lepodisiran did not induce significant changes in body weight of the pAlb-hLPA-Tg(V2) mice. 6-8-week-old, male pAlb-hLPA-Tg(V2) mice were assigned to four groups for saline or Leposiran (n=5 in each group). Following a single subcutaneous dose in each group, (A) body weight and (B) body weight change were measured.

image.png

Fig.4 Detection of human LPA inhibition by Lepodisiran. Lepodisiran significantly reduced serum human LPA levels in a dose-dependent manner. 6-8-week-old, male pAlb-hLPA-Tg(V2) mice were assigned to four groups for saline or Leposiran (n=5 in each group). Following a single subcutaneous dose in each group, (A) serum hLPA levels and (B) hLPA inhibition were measured.


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more